Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer
- Authors:
- Fuqiang Yin
- Xia Liu
- Danrong Li
- Qi Wang
- Wei Zhang
- Li Li
-
Affiliations: Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Center for Translational Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China - Published online on: February 8, 2013 https://doi.org/10.3892/ijo.2013.1819
- Pages: 1305-1316
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Balch C, Huang TH, Brown R and Nephew KP: The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol. 191:1552–1572. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar | |
|
Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fraser M, Bai T and Tsang BK: Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer. 122:534–546. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr and Siddik ZH: Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res. 5:655–663. 1999. | |
|
Zhou C, Smith JL and Liu J: Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene. 22:2396–2404. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK and Zhang W: Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 306:1557–1565. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu L, Wu A and Jiang K: Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells. Zhonghua Fu Chan Ke Za Zhi. 31:169–172. 1996.(In Chinese). | |
|
Benoit DS, Henry SM, Shubin AD, Hoffman AS and Stayton PS: pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol Pharm. 7:442–455. 2010. View Article : Google Scholar | |
|
Itamochi H: Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem. 1:209–220. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar | |
|
Narod S, Moody J, Rosen B, Fan I, Risch A, Sun P and McLaughlin J: Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clin Genet. June 8–2012.(Epub ahead of print). | |
|
Szabova L, Yin C, Bupp S, et al: Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 72:1–13. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Thangaraju M, Kaufmann SH and Couch FJ: BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem. 275:33487–33496. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Connor JP, Felder M, Kapur A and Onujiogu N: DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1. BMC Cancer. 12:1762012. View Article : Google Scholar | |
|
Quinn JE, James CR, Stewart GE, et al: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 13:7413–7420. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yellaboina S, Tasneem A, Zaykin DV, Raghavachari B and Jothi R: DOMINE: a comprehensive collection of known and predicted domain-domain interactions. Nucleic Acids Res. 39:D730–D735. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Raghavachari B, Tasneem A, Przytycka TM and Jothi R: DOMINE: a database of protein domain interactions. Nucleic Acids Res. 36:D656–D661. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jenssen TK, Laegreid A, Komorowski J and Hovig E: A literature network of human genes for high-throughput analysis of gene expression. Nat Genet. 28:21–28. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Mostafavi S, Ray D, Warde-Farley D, Grouios C and Morris Q: GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol. 9(Suppl 1): S42008. View Article : Google Scholar : PubMed/NCBI | |
|
Baitaluk M, Sedova M, Ray A and Gupta A: BiologicalNetworks: visualization and analysis tool for systems biology. Nucleic Acids Res. 34:W466–W471. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Dweep H, Sticht C, Pandey P and Gretz N: miRWalk - database: prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847. 2011. | |
|
Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M and Hatzigeorgiou AG: DIANA-mirPath: integrating human and mouse microRNAs in pathways. Bioinformatics. 25:1991–1993. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Baggiolini M, Dewald B and Moser B: Human chemokines: an update. Annu Rev Immunol. 15:675–705. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Liu L, Qiu X, et al: CCL21/CCR7 prevents apoptosis via the ERK pathway in human non-small cell lung cancer cells. PLoS One. 7:e332622012. View Article : Google Scholar : PubMed/NCBI | |
|
Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF and Wu CM: CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J Gastroenterol. 18:1249–1256. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Liu L, Qiu X, et al: CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells. PLoS One. 6:e211192011. View Article : Google Scholar : PubMed/NCBI | |
|
Yousefieh N, Hahto SM, Stephens AL and Ciavarra RP: Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron. 2:59–67. 2009. View Article : Google Scholar | |
|
Zhang H, Widegren E, Wang DW and Sun XF: SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer. Tumour Biol. 32:1225–1231. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hambrock HO, Nitsche DP, Hansen U, Bruckner P, Paulsson M, Maurer P and Hartmann U: SC1/hevin. An extracellular calcium-modulated protein that binds collagen I. J Biol Chem. 278:11351–11358. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Girard JP and Springer TA: Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. J Biol Chem. 271:4511–4517. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Qian J, Yu G, Chen Y, Liu K, Li J and Wang J: Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol. 105:31–37. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y and Zheng S: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol. 17:2028–2036. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sullivan MM and Sage EH: Hevin/SC1, a matricellular glyco-protein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol. 36:991–996. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mintz MB, Sowers R, Brown KM, et al: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 65:1748–1754. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Song J, Wang X, Lei C, et al: Fusion of chemotactic peptide to a single-chain bi-specific antibody (scBsAb) potentiates its cytotoxicity to target tumour cells. Biotechnol Appl Biochem. 45:147–154. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Biade S, Marinucci M, Schick J, et al: Gene expression profiling of human ovarian tumours. Br J Cancer. 95:1092–1100. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X, Zhai C, Gopalakrishnan V and Buchanan BG: Automatic annotation of protein motif function with Gene Ontology terms. BMC Bioinformatics. 5:1222004. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Chen LP, Huang R and Huang RP: Inhibition of IL-6 and IL-8 enhances chemosensitization in multidrug resistant human breast cancer cells. AACR Meeting Abstracts. 2005:1199-c2005. | |
|
Duan Z, Feller AJ, Penson RT, Chabner BA and Seiden MV: Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 5:3445–3453. 1999. | |
|
Soon WW, Miller LD, Black MA, et al: Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med. 3:451–464. 2011. View Article : Google Scholar | |
|
Chen T, Lee TR, Liang WG, Chang WS and Lyu PC: Identification of trypsin-inhibitory site and structure determination of human SPINK2 serine proteinase inhibitor. Proteins. 77:209–219. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kutuzov MA, Bennett N and Andreeva AV: Protein phosphatase with EF-hand domains 2 (PPEF2) is a potent negative regulator of apoptosis signal regulating kinase-1 (ASK1). Int J Biochem Cell Biol. 42:1816–1822. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gibadulinova A, Tothova V, Pastorek J and Pastorekova S: Transcriptional regulation and functional implication of S100P in cancer. Amino Acids. 41:885–892. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu W, Xu H, Zhu D, et al: miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hong JH, Lee E, Hong J, Shin YJ and Ahn H: Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int. 90:113–117. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Dhar DK, Nagasue N, Yoshimura H, et al: Overexpression of P-glycoprotein in untreated AFP-producing gastric carcinoma. J Surg Oncol. 60:50–54. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Z, Wang M, Wang L, Wang Y, Zhao X, Rao Q and Wang J: Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res. 33:891–897. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z and Chen S: ER regulates an evolutionarily conserved apoptosis pathway. Biochem Biophys Res Commun. 400:34–38. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, Muggia FM and Reed E: Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ Health Perspect. 98:53–59. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Jo H, Loison F, Hattori H, Silberstein LE, Yu H and Luo HR: Natural product Celastrol destabilizes tubulin heterodimer and facilitates mitotic cell death triggered by microtubule-targeting anti-cancer drugs. PLoS One. 5:e103182010. View Article : Google Scholar | |
|
Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Herr DR: Potential use of G protein-coupled receptor-blocking monoclonal antibodies as therapeutic agents for cancers. Int Rev Cell Mol Biol. 297:45–81. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ma Q, Zhang ZS, Zhang YL and Lai ZS: Relationship between multidrug resistance in human colon carcinoma LoVo/Adr cell line and intracellular calcium ion concentration. Ai Zheng. 21:846–849. 2002.(In Chinese). | |
|
Liang X and Huang Y: Intracellular free calcium concentration and cisplatin resistance in human lung adenocarcinoma A549 cells. Biosci Rep. 20:129–138. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Nan A, Ghandehari H, Hebert C, Siavash H, Nikitakis N, Reynolds M and Sauk JJ: Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. J Drug Target. 13:189–197. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Westhoff MA and Fulda S: Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat. 12:127–136. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Benatar T, Amemiya Y, Yang W and Seth A: Insulin-like-growth factor-binding-protein 7: an antagonist to breast cancer. Breast Cancer - Focusing Tumor Microenvironment, Stem cells and Metastasis. Gunduz M: InTech; Rijeka: pp. 39–68. 2011 | |
|
Heesch S, Schlee C, Neumann M, et al: BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia. 24:1429–1436. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lane TF, Iruela-Arispe ML, Johnson RS and Sage EH: SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol. 125:929–943. 1994.PubMed/NCBI | |
|
Girard JP and Springer TA: Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity. 2:113–123. 1995. View Article : Google Scholar | |
|
Socha MJ, Said N, Dai Y, et al: Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia. 11:126–135. 2009.PubMed/NCBI | |
|
Tai IT, Dai M, Owen DA and Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest. 115:1492–1502. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
De Milito A and Fais S: Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother. 6:1049–1054. 2005.PubMed/NCBI | |
|
Logothetis CJ, Hossan EA and Smith TL: SMS 201–995 in the treatment of refractory prostatic carcinoma. Anticancer Res. 14:2731–2734. 1994. | |
|
Matrone A, Grossi V, Chiacchiera F, et al: p38alpha is required for ovarian cancer cell metabolism and survival. Int J Gynecol Cancer. 20:203–211. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kapitza S, Pongratz M, Jakupec MA, et al: Heterocyclic complexes of ruthenium (III) induce apoptosis in colorectal carcinoma cells. J Cancer Res Clin Oncol. 131:101–110. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Yokomizo A, Ono M, Nanri H, et al: Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 55:4293–4296. 1995.PubMed/NCBI | |
|
Turk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM and Szakacs G: Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res. 69:8293–8301. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Van Jaarsveld MT, Helleman J, Berns EM and Wiemer EA: MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol. 42:1282–1290. 2010.PubMed/NCBI | |
|
Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yang N, Kaur S, Volinia S, et al: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 68:10307–10314. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Boren T, Xiong Y, Hakam A, et al: MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 113:249–255. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK and Kakar SS: MicroRNA signature of cis-platin resistant vs. cisplatin sensitive ovarian cancer cell lines. J Ovarian Res. 4:172011. View Article : Google Scholar : PubMed/NCBI | |
|
Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F and Burdette JE: Glycogen synthase kinase 3beta inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drugs. 22:978–985. 2011.PubMed/NCBI | |
|
Su HY, Lai HC, Lin YW, et al: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer. 127:555–567. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bellone S, Siegel ER, Cocco E, et al: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer. 19:860–866. 2009. View Article : Google Scholar | |
|
Chen JY, Shen C, Yan Z, Brown DP and Wang M: A systems biology case study of ovarian cancer drug resistance. Comput Syst Bioinformatics Conf. 389–398. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI | |
|
Miller DH, Fischer AK, Chu KF, Burr R, Hillenmeyer S, Brard L and Brodsky AS: T0901317 inhibits cisplatin-induced apoptosis in ovarian cancer cells [corrected]. Int J Gynecol Cancer. 21:1350–1356. 2011.PubMed/NCBI | |
|
Trinh XB, van Dam PA, Dirix LY, Vermeulen PB and Tjalma WA: The rationale for mTOR inhibition in epithelial ovarian cancer. Expert Opin Investig Drugs. 18:1885–1891. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Feng Q, Kim JM, et al: Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology. 142:370–380. 2001.PubMed/NCBI | |
|
Luo T, Yu J, Nguyen J, et al: Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. Proc Natl Acad Sci USA. 109:10175–10180. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nessa MU, Beale P, Chan C, Yu JQ and Huq F: Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res. 32:53–59. 2012.PubMed/NCBI | |
|
Kumaran GC, Jayson GC and Clamp AR: Antiangiogenic drugs in ovarian cancer. Br J Cancer. 100:1–7. 2009. View Article : Google Scholar | |
|
Zhang Y, Cheng Y, Ren X, et al: NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene. 31:1055–1064. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Buys TP, Chari R, Lee EH, et al: Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. Genes Chromosomes Cancer. 46:1069–1079. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Auner V, Sehouli J, Oskay-Oezcelik G, Horvat R, Speiser P and Zeillinger R: ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol. 117:198–201. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H and Katano M: Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. 30:2041–2048. 2010.PubMed/NCBI | |
|
Wang S, Li W, Xue Z, et al: Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin. Mol Carcinog. Jun 5–2012.(Epub ahead of print). View Article : Google Scholar | |
|
Leon-Galicia I, Diaz-Chavez J, Garcia-Villa E, et al: Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells. Eur J Cancer Prev. 22:11–20. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Han W, Pan H, Chen Y, et al: EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 6:e186912011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and Jiang BH: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chung AS, Kowanetz M, Wu X, et al: Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol. 227:404–416. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Waldner MJ and Neurath MF: Targeting the VEGF signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:5–13. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ishdorj G, Li L and Gibson SB: Regulation of autophagy in hematological malignancies: role of reactive oxygen species. Leuk Lymphoma. 53:26–33. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Yang M, Kang R, et al: DAMP-mediated autophagy contributes to drug resistance. Autophagy. 7:112–114. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fisher C, Coleman T and Plant N: Probabilistic orthology analysis of the ATP-binding cassette transporters: implications for the development of multiple drug resistance phenotype. Drug Metab Dispos. 40:1397–1402. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shukla S, Chen ZS and Ambudkar SV: Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat. 15:70–80. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol. 205:275–292. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson SW, Ozols RF and Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer. 71:644–649. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Sharan R, Ulitsky I and Shamir R: Network-based prediction of protein function. Mol Syst Biol. 3:882007. View Article : Google Scholar : PubMed/NCBI | |
|
Behm-Ansmant I, Rehwinkel J and Izaurralde E: MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D and Calin GA: miRNAs and their potential for use against cancer and other diseases. Future Oncol. 3:521–537. 2007. View Article : Google Scholar : PubMed/NCBI |
